Dr. Gaziel is a distinguished medical oncology professional who brings over 20 years of clinical and research experience from global pharmaceutical companies. Dr. Gaziel’s focus is on early- and late-stage development of oncology and biologic therapeutics, guiding drug candidates through initial innovation to proof-of-concept trials and beyond. Dr. Gaziel is a clinical oncologist by training and previously served as Senior Medical Director at Genmab, where she directed clinical development of multiple cutting-edge immuno-oncology assets. At Y-mAbs Therapeutics, she shaped the clinical programs for unique treatments for the treatment of relapsed or refractory neuroblastoma in pediatric patients including naxitamab (DANYELZA^®). For Eli Lilly she led the Nordic team efforts supporting clinical trials and regulatory activities in the high-profile global oncology programs of abemaciclib (VERZENIOS^®) and ramucirumab (CYRAMZA^®).